最大使用条件下防晒霜涂抹对防晒活性成分血浆浓度的影响:一项随机临床试验
该随机临床试验在美国一期临床药理学单位纳入24名健康志愿者,随机分配至4种市售防晒霜(喷雾1、喷雾2、乳液、乳膏各6人),按每平方厘米2毫克涂覆75%体表面积、每日4次连续4天,7天内采集30份血样。结果显示4种产品在第一天4次涂抹后全身浓度均超过0.5纳克/毫升;最常见不良事件为皮疹,每种防晒霜各1人发生。作者结论称该初步研究支持需进一步研究以确定这些发现的临床意义,但结果不提示个体应停用防晒霜。
要点
- 4种市售防晒霜在最大使用条件下,第一天4次涂抹后全身浓度均超过FDA设定的0.5纳克/毫升阈值。
- 阿伏苯宗几何均值最大血浆浓度:喷雾1为4.0纳克/毫升,喷雾2为3.4纳克/毫升,乳液为4.3纳克/毫升,乳膏为1.8纳克/毫升。
- 氧苯酮几何均值最大血浆浓度:喷雾1为209.6纳克/毫升,喷雾2为194.9纳克/毫升,乳液为169.3纳克/毫升。
核心结论
- 在这项纳入健康志愿者的初步研究中,最大使用条件下涂抹4种市售防晒霜导致血浆浓度超过FDA为可能豁免某些非临床毒理学研究而设定的阈值。
- 防晒成分的全身吸收支持需进一步研究以确定这些发现的临床意义。
- 这些结果不提示个体应停用防晒霜。
研究设计与样本
- 随机临床试验,在美国一期临床药理学单位开展,纳入24名健康志愿者,入组时间为2018年7月至2018年8月。
- 参与者随机分配至4种防晒霜:喷雾1(n=6)、喷雾2(n=6)、乳液(n=6)、乳膏(n=6)。
- 每平方厘米2毫克防晒霜涂覆75%体表面积,每日4次连续4天,7天内每名参与者采集30份血样。
- 主要结局为阿伏苯宗最大血浆浓度;次要结局为氧苯酮、奥克立林和依莰舒最大血浆浓度。
- 24名随机参与者中23名(96%)完成试验;平均年龄35.5岁(SD,1.5),女性12名(50%),黑人或非裔美国人14名(58%)。
主要发现
- 阿伏苯宗几何均值最大血浆浓度:喷雾1为4.0纳克/毫升(变异系数6.9%),喷雾2为3.4纳克/毫升(变异系数77.3%),乳液为4.3纳克/毫升(变异系数46.1%),乳膏为1.8纳克/毫升(变异系数32.1%)。
- 氧苯酮几何均值最大血浆浓度:喷雾1为209.6纳克/毫升(变异系数66.8%),喷雾2为194.9纳克/毫升(变异系数52.4%),乳液为169.3纳克/毫升(变异系数44.5%);乳膏未报告该成分数值。
- 奥克立林几何均值最大血浆浓度:喷雾1为2.9纳克/毫升(变异系数102%),喷雾2为7.8纳克/毫升(变异系数113.3%),乳液为5.7纳克/毫升(变异系数66.3%),乳膏为5.7纳克/毫升(变异系数47.1%)。
- 依莰舒几何均值最大血浆浓度为乳膏1.5纳克/毫升(变异系数166.1%);其他3种产品未报告该成分数值。
- 所有4种产品在第一天4次涂抹后全身浓度均超过0.5纳克/毫升;最常见不良事件为皮疹,每种防晒霜各1名参与者发生。
关键数值与推荐
- FDA指南指出,全身吸收大于0.5纳克/毫升或存在安全性担忧的防晒活性成分应进行非临床毒理学评估,包括全身致癌性及额外的发育和生殖研究。
- 本研究检测的活性成分为阿伏苯宗、氧苯酮、奥克立林和依莰舒。
- 全身浓度大于0.5纳克/毫升的阈值在本研究中用于与FDA指南比较。
临床怎么用
- 作者结论指出,这些结果不提示个体应停用防晒霜。
- 作者结论指出,防晒成分的全身吸收支持需进一步研究以确定这些发现的临床意义。
局限性
- 原文称本研究为初步研究。
- 作者结论指出需进一步研究以确定这些发现的临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The US Food and Drug Administration (FDA) has provided guidance that sunscreen active ingredients with systemic absorption greater than 0.5 ng/mL or with safety concerns should undergo nonclinical toxicology assessment including systemic carcinogenicity and additional developmental and reproductive studies. OBJECTIVE: To determine whether the active ingredients (avobenzone, oxybenzone, octocrylene, and ecamsule) of 4 commercially available sunscreens are absorbed into systemic circulation. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted at a phase 1 clinical pharmacology unit in the United States and enrolling 24 healthy volunteers. Enrollment started in July 2018 and ended in August 2018. INTERVENTIONS: Participants were randomized to 1 of 4 sunscreens: spray 1 (n = 6 participants), spray 2 (n = 6), a lotion (n = 6), and a cream (n = 6). Two milligrams of sunscreen per 1 cm2 was applied to 75% of body surface area 4 times per day for 4 days, and 30 blood samples were collected over 7 days from each participant. MAIN OUTCOMES AND MEASURES: The primary outcome was the maximum plasma concentration of avobenzone. Secondary outcomes were the maximum plasma concentrations of oxybenzone, octocrylene, and ecamsule. RESULTS: Among 24 participants randomized (mean age, 35.5 [SD, 1.5] years; 12 (50%] women; 14 [58%] black or African American; 14 [58%]), 23 (96%) completed the trial. For avobenzone, geometric mean maximum plasma concentrations were 4.0 ng/mL (coefficient of variation, 6.9%) for spray 1; 3.4 ng/mL (coefficient of variation, 77.3%) for spray 2; 4.3 ng/mL (coefficient of variation, 46.1%) for lotion; and 1.8 ng/mL (coefficient of variation, 32.1%). For oxybenzone, the corresponding values were 209.6 ng/mL (66.8%) for spray 1, 194.9 ng/mL (52.4%) for spray 2, and 169.3 ng/mL (44.5%) for lotion; for octocrylene, 2.9 ng/mL (102%) for spray 1, 7.8 ng/mL (113.3%) for spray 2, 5.7 ng/mL (66.3%) for lotion, and 5.7 ng/mL (47.1%) for cream; and for ecamsule, 1.5 ng/mL (166.1%) for cream. Systemic concentrations greater than 0.5 ng/mL were reached for all 4 products after 4 applications on day 1. The most common adverse event was rash, which developed in 1 participant with each sunscreen. CONCLUSIONS AND RELEVANCE: In this preliminary study involving healthy volunteers, application of 4 commercially available sunscreens under maximal use conditions resulted in plasma concentrations that exceeded the threshold established by the FDA for potentially waiving some nonclinical toxicology studies for sunscreens. The systemic absorption of sunscreen ingredients supports the need for further studies to determine the clinical significance of these findings. These results do not indicate that individuals should refrain from the use of sunscreen. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03582215.
引用
- Matta MK, Zusterzeel R, Pilli NR, et al. Effect of Sunscreen Application Under Maximal Use Conditions on Plasma Concentration of Sunscreen Active Ingredients: A Randomized Clinical Trial. JAMA. 2019. PMID: 31058986. doi:10.1001/jama.2019.5586
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。